How will the results of NRG GU006 and the use of the PAM50 genomic classifier impact treatment for recurrent prostate cancer?

This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by the Clinical Trials Session Presentation "A Double-Blinded Placebo-Controlled Biomarker Stratified Randomized Trial of Apalutamide (APA) and Radiotherapy for Recurrent Prostate Cancer (NRG GU006, BALANCE trial)" by Dr. Daniel Spratt.

Answer from: Radiation Oncologist at Community Practice

Top line results: The prostate cancer-adapted PAM50 gene expression biomarker was validated in the NRG GU006 randomized trial to predict the differential benefit of hormone therapy, specifically apalutamide monotherapy, for patients with recurrent prostate cancer after radical prostatectomy being t...

Comments

Radiation Oncologist at Delaware Valley Urology Cancer Treatment Center
Can you please clarify this statement, which is co...

Radiation Oncologist at Case Western Reserve University/ University Hospitals Seidman Cancer Center
Dr. @Kornmehl, Great questions. TAILORx did not ...

Radiation Oncologist at Delaware Valley Urology Cancer Treatment Center
Thank you for the clarification, Dr. @Spratt.

Please select the option that best describes you:

How will the results of NRG GU006 and the use of the PAM50 genomic classifier impact treatment for recurrent prostate cancer?

Related Questions